Loncom Pharma’s Anamorelin HCl APIs target the improvement of appetite and body mass in individuals suffering from cachexia associated with cancer. These APIs mimic ghrelin, binding to receptors in the brain to stimulate growth hormone release and appetite.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
